India orders Sun Pharma to halt eye-care drug production at plant after quality lapses
Indian drug regulators have ordered Sun Pharmaceutical Industries to halt production of ophthalmic drugs at its Assam plant due to quality management failures. This follows a voluntary recall of several eye-care brands and comes amid broader scrutiny of Indian pharmaceutical quality standards.
Why it matters
The shutdown impacts a key manufacturing hub for India's largest pharmaceutical company and reflects ongoing concerns regarding drug safety and regulatory compliance.
HYDERABAD Indian drug regulators ordered Sun Pharmaceutical Industries to stop manufacturing, selling and distributing ophthalmic products made at its Assam facility after finding failure in its quality management system, documents reviewed by Reuters showed. The Central Drugs Standard Control Organisation and the office of Drugs Controller Assam ordered the shutdown on August 20 after a joint federal-state inspection of the facility identified lapses in the system meant to ensure product quality and safety, following Sun Pharma’s move in July to voluntarily recall about 11 eye-care brands. Sun Pharma Q2 profit plunges 36% on exceptional charges despite revenue growth Sun Pharma Q2 profit plunges 36% on exceptional charges despite revenue growth Excluding the exceptional items, adjusted net profit stood at ₹3,162 crore.
Also covering this story
One other newsroom covered this event. We read that version too.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in